We mined novel uremic toxin (UT) metabolomics/gene databases, and analyzed the expression changes of UT receptors and UT synthases in chronic kidney disease (CKD) and cardiovascular disease (CVD). We made the following observations: 1) UTs represent only 1/80 th of human serum smallmolecule metabolome; 2) Some UTs are increased in CKD and CVD; 3) UTs either induce or suppress the expression of inflammatory molecules; 4) The expression of UT genes is significantly modulated in CKD patients, and coronary artery disease (CAD) patients; 5) The expression of UT genes is upregulated by caspase-1 and TNF-alpha pathways but is inhibited in regulatory T cells. These results demonstrate that UTs are selectively increased, and serve as danger signal-associated molecular patterns (DAMPs) and homeostasis-associated molecular patterns (HAMPs) that modulate inflammation. These results also show that some UT genes are upregulated in CKD and CAD via caspase-1/inflammatory cytokine pathways, rather than by purely passive accumulation.
INTRODUCTION
The incidence of chronic kidney disease (CKD) is increasing worldwide. Atherosclerosis-related cardiovascular disease (CVD) is a major cause of mortality in patients with CKD (1). We and others have previously shown that hyperlipidemia, along with other CVD stressors, such as hyperglycemia, hyperhomocysteinemia, and chronic kidney disease, promote atherosclerosis and vascular inflammation via several mechanisms (2) (3) (4) (5) (6) (7) . These mechanisms include endothelial cell (EC) activation and injury (2, (8) (9) (10) ; mitochondrial reactive oxygen species (3); monocyte recruitment and differentiation (11, 12) ; decreased It has been suggested that CKD uremic toxins (UTs), in combination with other risk factors, cause oxidative stress, low-grade inflammation with increased circulating cytokines and endothelial dysfunction (20, 23) . One of the well-characterized UTs is carbamylated LDL (cLDL) (24) . Urea spontaneously dissociates to form cyanate (OCN -), which modifies proteins in a process referred to as carbamylation. The active form of cyanate, isocyanic acid, reacts irreversibly with the amino acids in apolipoprotein B, the protein component of LDL to form cLDL (24) . Protein carbamylation has been found in atherosclerotic plaque and serum level of cLDL is increased significantly in patients with ESRD. In addition, cLDL, but not native LDL, has been shown to have all of the major biological effects relevant to atherosclerosis, including EC injury and dysfunction by binding to oxLDL receptor (LOX-1), increased expression of cell adhesion molecules, monocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation (24) (25) (26) . However, the mechanistic link between sensing UTs and vascular inflammation remains unknown. Cellular "receptors", which can recognize the risk factors for vascular inflammation and atherogenesis, have been intensively researched. The role of pathogen-associated molecular patterns (PAMPs) and danger signal-associated molecular patterns (DAMPs) receptors has been characterized recently as bridging innate immune sensory systems for exogenous infectious agents and endogenous metabolic dangers to initiation of inflammation (27) . More than 14 groups of endogenous metabolites have been proposed to act as danger signals via various DAMP recognition receptors to promote inflammation (28, 29) . The Toll-like receptors (TLRs), mainly localized in the plasma membrane, recognize a variety of conserved microbial PAMPs and metabolic DAMPs, thereby functioning as PAMP and DAMP receptors, and promote inflammatory gene transcription. As we reported previously, for inflammation-privileged tissues, such as cardiovascular tissues in which inflammasome component genes are not constitutively expressed, TLRs work in synergy with upregulated cytosol-located sensing receptor families including NLRs (NOD (nucleotide binding and oligomerization domain)-like receptors) (30) . In the cytosol, nucleus and extracellular compartment as we most recently reported, these inflammasome components and pro-caspase-1 assemble into a protein complex termed inflammasome, which subsequently activates caspase-1 after recognizing endogenous DAMPs (31) . In this way, TLRs mediate upregulation, activation of a range of inflammatory genes and acceleration of vascular inflammation and atherosclerosis (2, 32) . After recognizing a paradox that classical DAMP receptors may not be able to bind with high affinity to all of the endogenous metabolite-derived danger signals, we proposed that endogenous metabolite-derived danger signals are conditional DAMPs, which together with our newly proposed homeostasis (anti-inflammatory)-associated molecular patterns (HAMPs), may use both intrinsic receptors and classical DAMP receptors to regulate inflammation (33) . However, the issue of whether UTs serve as endogenous metabolitederived danger signals to activate DAMPs receptors including TLRs and NLRs/inflammasome/caspase-1 remains unknown. To demonstrate a proof of principle that classical DAMP receptors play a critical role in accelerating CKD-promoted vascular inflammation, we recently reported that NLR-inflammasome caspase-1 pathway plays an essential role in sensing CKD-derived DAMPs, and in significantly promoting neointimal hyperplasia formation in carotid artery in 5/6 nephrectomy-induced CKD mouse model (6) .
In this study, we collected 116 experimentally identified UTs and examined two novel hypotheses that: first, UTs can serve as conditional proinflammatory DAMPs, or anti-inflammatory HAMPs, and modulate inflammation; and second, in addition to passive accumulation due to decreased glomeruli filtration in CKD, elevation of UTs can be partially induced by classical DAMP receptors such as TLRs, NLR-inflammasome-activated caspase-1, and other pro-inflammatory cytokines as well as be inhibited by CD4
+

Foxp3
+ regulatory T cells (Tregs). Using a © 1996-2018 novel database mining approach, our results have demonstrated for the first time that UTs are selectively increased, and serve as DAMPs and HAMPs to modulate inflammation (30, 34) ; that UT genes including protein carried UT receptors and UT synthases can be upregulated in CKD and CAD presumably via caspase-1/inflammatory cytokine pathways; and that elevation of UTs does not result from purely passive accumulation. The findings have significantly improved our understanding of the molecular mechanisms underlying the roles of UTs in accelerating vascular inflammation and UT generation, which provide novel insights for the future development of novel therapeutics for CKD-and CKD-promoted cardiovascular disease and other diseases.
MATERIALS AND METHODS
Uremic toxins
We analyzed 116 experimentally verified UTs that were identified in recently published reports and review (35) (36) (37) . The experimental method used in the identification of those UTs was mass spectrometry.
Expression profiles of uremic toxins and related enzymes and receptors in disease model
Gene expression profiles of the identified UTs were analyzed in 13 microarray datasets extracted from NIH-GEO database (http://www.ncbi.nlm.nih.gov/ gds/) (Figure 1 ). The information regarding metabolite synthesis pathway enzymes was extracted from the Human Metabolome Database (http://www.hmdb.ca/). The information related to genes encoding protein/ peptide-based UTs, enzymes, and receptors was obtained from the NCBI-Gene database (http://www. ncbi.nlm.nih.gov/gene/). The UTs which exist in the exosomes are examined in the ExoCarta database (http://www.exocarta.org/) . The information of the UTs can be identified in NIH-NCBI-PubChem Database (https://pubchem.ncbi.nlm.nih.gov/). Specific samples were chosen as disease or treatment groups and parallel control. The number of samples was always greater than 3, except for the pooled samples. We selected the genes with significant expression changes (p<0.0.5) in the microarray dataset and examined the fold change of the genes of our interest. The genes with more than 1-fold expression change were defined as the upregulated genes while genes with their expression changes less than 1-fold were defined as downregulated genes.
Ingenuity pathway analysis
In order to categorize clinical functions and molecular and cellular functions related to the identified genes in our microarray analysis, the Ingenuity Pathway Analysis (IPA, Ingenuity Systems, www.ingenuity.com) was used. The differentially expressed genes were identified and uploaded into IPA for analysis. The Core pathways analysis was used to identify molecular and cellular pathways.
RESULTS
Uremic toxins represent 1/80
th of human serum small-molecule metabolome
To identify the molecular mechanisms of how CKD accelerates vascular inflammation, we hypothesized that CKD selectively accumulates a specific group of endogenous metabolites as UTs (Figure 2 ). We focused on analyzing the experimentally identified UTs. As shown in Table 1 , 116 UTs have been identified (35) (36) (37) , including four categories: 1) 53 small molecules (<500 Daltons); 2) 30 protein-bound molecules; 3) 39 middle-sized molecules, including protein/peptide-based (>500 Daltons); and 4) 15 microbe-generated toxins (38) . Among 53 small-molecule toxins, only one receptor for inosine has been identified. Of note, the Human Metabolome Database identification numbers (IDs) for three small-molecule toxins were not found in the database; and the NIH-NCBI-PubChem Database IDs for five small-molecule toxins were not found in the database, suggesting these toxins are newly identified. In addition, 12 out of 30 protein-bound molecule toxins were found to have their own intrinsic receptors. Moreover, 20 out of 35 protein/peptidebased toxins had their own receptors, including several cytokines such as interleukin-18 (IL-18), IL-6, IL-1β, leptin, tumor necrosis factor-α (TNF-α). One of the microbe-generated UTs, pentosidine, can bind to the receptor for advanced glycation end products (RAGE) (39) . As shown in Figure 3 , those toxins, whose intrinsic receptors have not been identified, may also use classical DAMP receptors and nuclear receptors (for lipophilic toxins) to initiate inflammationregulatory functions (29, (40) (41) (42) . Furthermore, as shown in Table 2 , our analysis on an exosome database (ExoCarta database; http://www.exocarta. org/) found that 6 out of 34 protein/peptide-based toxins have been found in exosomes in the plasma, suggesting that those toxins can promote/modulate the target cells for inflammation via exosome uptake mechanism with and without binding to their own receptors (43) .
We first argued that if the generation of UTs results from accumulation of endogenous metabolites due to decreased glomeruli filtration in CKD, the compositions of UTs should be proportionally at least similar to, if not the same as, the human plasma metabolome. To our surprise, the most comprehensive Human Metabolome Database (HMDB) (version 3.6.) contains 41,993 metabolite entries, including both water-soluble and lipid-soluble Figure 1 . Flow chart of database mining strategy and three parts of data organization. A. We propose a new paradigm that uremic toxins are conditional pro-inflammatory danger-associated molecular pattern molecules (DAMPs) or anti-inflammatory homeostasis-associated molecular pattern molecules (our newly proposed HAMPs). Uremic toxins identified were classified into five groups based on their molecular sizes, molecular structure, molecular carrier and sources. The supporting data for this new paradigm were presented in Tables 3, 4 , 5 and Figure 2 , respectively. B. Potential pathways for toxin synthase gene upregulation and its signaling components in pathophysiological conditions. The seven pathways from # 3 to #9 were examined in this study. C. Identified uremic toxin genes, their expression data and potential underlying mechanisms were analyzed through data-mining. © 1996-2018 Figure 2 . Two novel hypotheses were examined on the expression levels of two sets of genes: First, uremic toxin generating enzymes (Table 6 ) and second, receptor complex components (Table 7) . We examined these two hypotheses to address how chronic kidney disease prone pathologies increase endogenous metabolites. Tumor necrosis factor-α 44 . In addition, the Serum Metabolome database collected 4,651 small-molecule metabolites found in human serum (http://www.serummetabolome.ca/). Although these datasets did not result from the same studies, our analysis results, tentatively taken together, showed that roughly 1/80 th , a very small fraction, of total human serum small-molecule metabolome were selectively accumulated in patients with CKD. If similar efficiencies were presumably achieved in identifying metabolites in human plasma and UTs with © 1996-2018 the current technologies, these analyses suggest that first, highly specific metabolites are highly selectively increased in the plasma of patients with CKD; and second, the high specificity of UTs accumulated in patients with CKD may not fully result from passive accumulation due to kidney malfunction in filtrating metabolites into urine. Instead, active mechanisms in synthesizing, processing, or converting these UTs may be the key regulating events for elevation of those toxins.
Classification of uremic toxins as
DAMPs or HAMPs
We recently proposed a new paradigm that pathologically elevated endogenous metabolites can be categorized into either conditional pro-inflammatory danger-associated molecular patterns (DAMPs) or anti-inflammatory homeostasis-associated molecular patterns (HAMPs) based on the roles of these metabolites in regulating inflammation (33) . To determine whether UTs are conditional DAMPs or HAMPs, we searched the Human Metabolome Database for the concentrations of toxins in physiological and pathological conditions. As shown in Table 3 , among 69 UTs that can be found in the Human Metabolome Database, 24 (35%) UTs are unique to CKD, the remaining 45 (65%) UTs are shared with other diseases/CVD risk factors, including various cancers, smoking, hypertension, Alzheimer's disease, cirrhosis, Canavan disease, etc. Among these 24 CKD UTs, 11 toxins had no reports on the physiological and pathological concentrations for comparison in the Human Metabolome Database. Seven CKD UTs were (47) ; phenol (9.1.5-fold); and taurocyamine (inducing convulsive seizures; https://www.wikigenes.org/e/ chem/e/68340.html) (7.8.-fold). The concentrations of two CKD toxins were actually decreased, including spermidine and spermine, which may cause the arrest in protein translation and cell growth (48) . Of note, the concentration changes in other diseases may either be increased or decreased in comparison to those of physiological conditions. These results suggest that these UTs that are changed in other diseases with opposite directions may contribute differently to the pathogenesis of those diseases. Among 24 CKD-specific UTs, the pathological concentrations of 10 toxins are available for the analysis, which are all increased in the pathological conditions, suggesting that these UTs are the conditional DAMPs.
Next, in order to verify UTs are conditional DAMPs or HAMPs, we examined our new hypothesis that UTs regulate inflammation, by either inducing or suppressing the expression of pro-inflammatory cytokines. To test this hypothesis, we searched for the experimental evidence that UTs can induce the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-18, IL-6, monocyte chemoattractant protein-1 (MCP-1), adhesion molecules, nuclear factor-kB (NF-κB) signaling molecules or mitogenactivated protein kinases (MAPK) signaling molecules, etc. As shown in Table 4 , among 92 free UTs, we found experimental reports showing that 32 UTs regulate inflammation in various cell types, with 20 promoting inflammation (as DAMPs, 62.5%) and 12 inhibiting inflammation (as HAMPs, 37.5.%). Moreover, as shown in Table 5 5) graft-versus-host disease signaling; 6) liver X nuclear receptor (LXR/RXR) activation (important regulators of cholesterol, fatty acid, and glucose homeostasis); 7) atherosclerosis signaling; 8) role of cytokines in mediating communications between immune cells; 9) differential regulation of cytokine production in macrophages and T helper cells by interleukin-17A (IL-17A) and IL-17F; and 10) IL-10 signaling. Once again, the IPA results strengthen our arguments that protein/peptide-based UTs have more pro-inflammatory than anti-inflammatory functions.
Uremic toxins facilitate CAD in patients with CKD
Our above-described results indicate that roughly 1/80 th , a very small fraction, of total human serum small-molecule metabolome was selectively accumulated in patients with CKD. The results suggest that the high specificity of UTs accumulated in patients with CKD may not result from passive accumulation due to kidney malfunction in filtrating metabolites into urine. We hypothesized that active mechanisms in synthesizing, processing, or converting these UTs may be the key regulating events for elevation of those toxins. To test this hypothesis, we first searched the toxin-generating enzymes. Among 69 UTs that can be found in the Human Metabolome Database, the 67 generating enzymes for 33 toxins can be found as shown in Table 6 . In addition, for 30 protein-bound UTs that may mainly bind to serum albumin, albumin-bound UTs may initiate inflammation-regulatory signaling via binding to five potential receptor complexes and their signaling components, including glycoproteins (Gp60, Gp30 and Gp18) (49-51); secreted protein acidic and rich in cysteine (SPARC, 8 genes) (50); neonatal Fc receptor (FcRn, 15 genes), cubilin-megalin (9 genes), and receptor for advanced glycation end products (RAGE, 23 genes), totaling 60 genes, as shown in Table 7 (50, 52) . Of note, some signaling components are shared among the receptor pathways. Moreover, as shown in Table 8 , among 34 protein/peptide-based UTs, the convertases for generating 14 out of 34 UTs have been identified. Furthermore, since exosomes are identified as a potential key carrier for CKD-driven cardiovascular disease, we found that 28 out of 169 genes that have been identified in exosomes in the ExoCarta exosome database, which indicate these UTs can use exosome uptake mechanisms to initiate inflammation-modulating pathways as shown in Table  9 (53). Taken together, we collected 169 genes that generate UTs (Table 6 ) and mediate UT signaling (Tables 7, 8 and 9 ).
To examine our hypothesis that the expression of these 169 genes is partially modulated in various diseases ( Figure 5 ) including CKD, we mined the microarray database in the NIH-GEO Datasets as shown in Table 10 . Our analysis of microarray experimental data indicated that 14 UT genes were upregulated; and another 14 UT genes were downregulated in the CKD kidney tubules. In addition, we found that 7 UT genes were upregulated; and another 9 UT genes were downregulated in the adipose tissues of patients with coronary artery disease (CAD). The striking similarities have been noted in upregulated proinflammatory pathways, including pro-inflammatory caspase-1 and caspase-1 substrate IL-18 in both CKD kidney tubules and CAD adipose tissue, suggesting that the same upregulated proinflammatory pathways underlie the pathogenesis of CKD and CAD. Moreover, we observed that 3 UT genes were upregulated and another 16 UT genes were slightly downregulated in the peripheral blood cells of patients with metabolic syndrome. Furthermore, we identified that 4 UT genes were upregulated and another 12 UT genes were slightly downregulated in the liver of patients with type 2 
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Interleukin-18 See Figure 2 for the rationale. diabetes, which were very similar to those observed in metabolic syndrome. Finally, we found that 9 UT genes were upregulated; and another 13 UT genes were slightly downregulated in the pancreas of patients with type 1 diabetes. Taken together, our results suggest that first, the upregulation of UTgenerating enzymes, protein-bound UT receptors and their signaling components, and convertases for protein/peptide-based UTs in CKD-related diseases at least partially contribute to increased concentrations of UTs; and second, some inflammation-modulating genes in UT generation and signaling pathways are upregulated in CKD, CAD and other metabolic diseases, pointing out the potential cross-talking mechanisms underlying the roles of UTs in facilitating CAD in patients with CKD.
The expressions of uremic toxin genes are modulated by cytokine pathways and regulatory T cells
Our above results indicated that the upregulation of UT-generating enzymes, proteinbound UT receptors and their signaling components, and convertases for protein/peptide-based UTs in CKD-related diseases at least partially contribute to increased concentrations of UTs. The mechanisms underlying this phenomenon are unknown. We hypothesize that elevated UTs in CKD can be sensed 
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Tumor necrosis factor-α TACE/ADAM17/CD156q ADAM17 6868 11733179 by classical DAMP receptor pathways (27, 54) . To test this hypothesis, we examined whether the expression of UT genes can be modulated in Toll-like receptor (TLR) pathways. The results showed, in Table 11 , that deficiencies of TLR2, TLR3 and TLR4 resulted in decreased expression of a number of genes (3 for TLR2 deficient (TLR2-/-) mice, 4 for TLR3-/-mice and 2 for TLR4-/-mice) as well as increased expression of genes (3 for TLR2-/-mice, 6 for TLR3-/-mice and 4 for TLR4-/-mice). In addition, we also examined a new hypothesis that the expression of UT genes can be modulated via caspase-1-dependent pathways since our reports showed that caspase-1 inflammasome pathways serve as a critical sensor to bridge the risk factors for cardiovascular diseases and initiation of vascular inflammation and atherosclerosis (2, 10, 17, 29, 30) . As shown in Table 12 , in caspase-1 knockout mice, 12 UT genes were downregulated and 5 UT genes were upregulated, suggesting that caspase-1 pathway plays an important role in promoting UT gene expression, much more than TLR pathways. Moreover, we examined another hypothesis that the expression of UT genes can be modulated by pro-inflammatory cytokines tumor necrosis factor-α (TNF-α), IL-1β, and interferon-γ (IFN-γ) pathways. As shown in Table 13 , in TNF-α-treated cells, 13 UT genes were upregulated, and 17 UT genes were downregulated; in IL-1β-treated cells, 2 UT genes were upregulated, and 3 UT genes were downregulated; and in IFN-γ-treated cells, 2 UT genes were upregulated and one UT gene was downregulated. The results suggest that first, caspase-1 pathway plays a more important role in promoting UT gene expression in comparison to other innate immune sensors DAMP receptors; and second, TNF-α pathway plays a more significant role in promoting the expression of UT genes in comparison to other pro-inflammatory cytokine pathways.
Finally, we wanted to examine a new hypothesis that CD4+Foxp3+ regulatory T cells (Tregs), one of the well-characterized immune tolerance cells, since we and others reported that Tregs play a critical role in suppressing vascular inflammation (13) (14) (15) ; and that Tregs are weakened and expanded poorly in CKD patients in hemodialysis (55) . As shown in Table 14 , in Tregs versus T effector cells, 11 UT genes were upregulated; and 21 UT genes were downregulated. These results suggest that immune suppression mechanism plays an important role in inhibiting the expression of UT genes.
DISCUSSION
As technology, including chromatographic methods (ion exchange chromatography, gas chromatography, HPLC), spectrophotometry, fluorometry, chemiluminescence, nephelometry, radioimmunometry, nuclear magnetic resonance and mass spectrometry, has improved, more UTs have been identified (56, 57) . This therefore allows for newly identified substances to be added to the list of the European Uremic Toxin (EUTox) Work Group on an ongoing basis, which provides an increasingly complex scenario on their toxicity (56) . It has been well documented that some protein/peptide-based UTs, including pro-inflammatory cytokines such as TNF-α, IL-1β, IL-18, and IFN-γ, promote vascular inflammation and other organ inflammation (56) . However, the issue of whether host innate immune system uses classical DAMP receptors to sense the elevation of all of other water-soluble and protein-bound UTs remains unknown. It is biochemically difficult for a few classical DAMP receptors, such as TLRs and NLRs, to bind with high affinity to all of those UTs and initiate inflammation efficiently, considering that reduced expression of TLR4 is found in uremic patients (58) .
To solve this problem, here, similar to what we reported recently for lysophospholipids, we examined our new hypothesis that UTs can serve as conditional pro-inflammatory DAMPs or antiinflammatory HAMPs, and that UTs use classical DAMP receptors as well as their intrinsic receptors including RAGE, and serum albumin-toxin receptors to modulate inflammation (54) . We have made the following new findings: 1) Chronic kidney disease selectively accumulates a very small fraction of human serum small-molecule metabolome, roughly 1/80 th , as UTs, suggesting that elevation of UTs is highly specific, and may not all result from dysfunctional glomerular filtration; 2) The serum concentrations of the majority of UTs are increased not only in CKD but also in other diseases, suggesting that some so-called UTs can also be increased when patients have no renal failure; 3) Protein-bound UTs either induce or suppress the expression of pro-inflammatory molecules rather than only promoting inflammation; 4) The expression of UT genes is modulated in the proximal tubules of patients with CKD, and adipose tissue of patients with coronary artery disease (CAD), more than in patients with metabolic syndrome and type 2 diabetes, pointing out the potential mechanisms underlying the roles of UTs in accelerating CAD more than other diseases in Since 1967, dialysis has been used a standard of care for patients with end-stage renal disease, with numerous new methods being used to complement the dialysis care (59, 60) . Dialysis is based on a classical hypothesis that passive accumulation of UTs is due to decreased glomerular filtration in CKD. However, our new findings revealed that UTs represent only 1/80 th of human serum smallmolecule metabolome, showing that UT accumulation is selective. In addition, considering that roughly 10% of the total metabolites have been identified in human serum metabolome (http://www.serummetabolome. ca), we can further postulate that actually CKD highly selectively accumulates a very tiny fraction of human serum small-molecule metabolome, roughly 1/800 th , as UTs (44) . Moreover, our results showed that the serum concentrations of the majority of UTs are increased not only in CKD but also in other diseases. Our results suggest that novel anti-caspase-1 and anti-TNF-α therapies and therapeutics in controlling UT-increased diseases together with dialysis could be developed.
Protein-bound UTs are poorly removed by current dialysis techniques because their size is larger than the pore size of dialysis membrane (61) . These protein-bound UTs, such as indoxyl sulfate, can induce upregulation of endothelial adhesion molecules, the hallmarks of endothelial cell activation, by binding to human aryl hydrocarbon receptor (AhR) to activate NFkB and mitogen-activated protein kinases (MAPKs), and NADPH oxidase to increase reactive oxygen species (ROS), both cytosolic ROS and mitochondrial ROS as we recently reported (3, 61, 62) . In addition, many UTs bind specifically to the Sudlow's sites I and II of human serum albumin mainly via electrostatic and/ or van der Waals forces (63) (64) (65) (66) . Five types of serum albumin receptors have been identified, including glycoproteins Gp60, Gp30 and Gp18, SPARC, the megalin/cubilin complex, RAGE and the neonatal Fc receptor (FcRn) (51) . Moreover, advanced glycation end products (AGE) in UTs can also use RAGE to trigger various intracellular events, such as oxidative stress and inflammation, leading to cardiovascular complications (67, 68). Taken together, our findings suggest that protein-bound UTs may not necessarily use classical DAMP receptors such as TLRs and NLRs to initiate inflammation, may use their intrinsic receptors including AhR, several serum albumin receptors and RAGE to promote inflammation. This conclusion supports our new classification of UTs as conditional danger-associated molecular patterns (DAMPs) or homeostasis-associated molecular patterns (HAMPs). The significance for classifying UTs as conditional DAMPs and HAMPs is that, this model will guide our future work of examining the pathways of new conditional DAMP receptors and HAMP receptors for novel therapeutic purposes.
Recent significant reports and reviews demonstrated a proof of principle that choline, derived by food (dietary) intake from intestine, requires intestinal bacterial enzyme-dependent transformation into trimethylamine (TMA), which is further absorbed into the blood circulation and is transformed into trimethylamine N-oxide (TMAO) in host liver by flavin containing monooxygenases (FMOs) (69) (70) (71) . TMAO is a newly characterized UT that exhibits genetic and dietary regulation, and promotes CKD, cardiovascular disease, impaired glucose intolerance, and atherosclerosis (72) (73) (74) (75) (76) (77) . We found that the expression of FMO1-5 is modulated by inflammatory pathways, including caspase-1 and TLR pathways. This new finding regarding TMAO generation pathway, together with other results presented in this study as well as other reports, allows us to propose a new working model ( Figure 6 ), which is summarized in the following points of view: First, rather than passive accumulation of endogenous metabolites, a very small fraction of human metabolome, roughly 1/80th of human plasma metabolome, or 1/800th of total human metabolome, eventually becomes selected to be UTs, suggesting that a highly selective mechanism is underlying the generation of UTs; Second, the expression of some UT synthases and signaling genes is significantly increased in patients with CKD, CAD and other diseases, suggesting that an increase in UTs; Third, the proof of principle demonstrated in TMAO pathway suggests that several factors, including diet, intestinal microbiome, as well as FMOs in host liver all contribute to microbiome-generated UTs; Fourth, regulatory T cells and anti-inflammatory cytokines may inhibit the gene expression of UT synthases and signaling pathway components; and Fifth, UTs serve as conditional DAMPs and HAMPs, whose intrinsic receptors, in addition to TLRs and NLRs, may initiate UT signaling for regulating vascular inflammation and other inflammatory diseases. These new findings have significantly improved our understanding of molecular mechanisms underlying the roles of UTs in accelerating vascular inflammation, and UT generation, which provide novel insights for the future development of new therapeutics for CKD and CKD-promoted cardiovascular disease and other diseases. 
CONCLUSIONS
Our new findings and others' recent reports allow us to propose a new working model (Figure 6 ), which is summarized in the following points of view: First, rather than passive accumulation of endogenous metabolites, a very small fraction of human metabolome, roughly 1/80th of human plasma metabolome, or 1/800th of total human metabolome, eventually becomes selected to be UTs, suggesting that a highly selective mechanism is underlying the generation of UTs; Second, the expression of some UT synthases and signaling genes is significantly increased in patients with CKD, CAD and other diseases, suggesting that an increase in UTs; Third, the proof of principle demonstrated in TMAO pathway suggests that several factors, including diet, intestinal microbiome, as well as FMOs in host liver all contribute to microbiome-generated UTs; Fourth, regulatory T cells and anti-inflammatory cytokines may inhibit the gene expression of UT synthases and signaling pathway components; and Fifth, UTs serve as conditional DAMPs and HAMPs, whose intrinsic receptors, in addition to TLRs and NLRs, may initiate UT signaling for regulating vascular inflammation and other inflammatory diseases. These new findings have significantly improved our understanding of molecular mechanisms underlying the roles of UTs in accelerating vascular inflammation, and UT generation, which provide novel insights for the future development of new therapeutics for CKD and CKDpromoted cardiovascular disease and other diseases.
